Abstract. Overexpression of tumor necrosis factor receptor-associated factor 4 (TRAF4) has been reported in several human malignancies; however its association with Girdin in breast cancer is unclear. The aim of the present study was to analyze the correlation, expression and nuclear and cytoplasmic localizations of TRAF4 and Girdin in breast cancer tissues. Tissue samples from 38 patients with breast cancer, the MCF-10A normal mammary epithelial cell line, the MCF-7 estrogen-receptor (ER)-positive and MDA-MB-231 ER-negative breast cancer cell lines were used in the present study. The results demonstrated that cytoplasmic expression of TRAF4 was positively correlated with cytoplasmic expression of Girdin. Furthermore, coexpression of TRAF4 and Girdin was highest in tissue samples from patients with lymph node metastases. Girdin was observed to be predominantly expressed in the cytoplasm of breast cancer cells; however TRAF4 promoted its translocation to the nucleus. These findings suggest that cytoplasmic expression of TRAF4 may be a novel potential marker for cell migration in breast cancer.
Introduction
Members of the tumor necrosis factor receptor-associated factor (TRAF) family are overexpressed in numerous types of human cancer and are involved in the activation of multiple signal transduction pathways (1) . TRAF4 has been demonstrated to promote Smurf1-mediated ubiquitination-dependent cell migration, transforming growth factor (TGF)-β receptor signaling and breast cancer metastasis (2, 3) . It also serves as a critical molecule in Akt activation in lung cancer (4) . The Akt pathway has been indicated to modulate TRAF4-mediated inhibition of Glut1 and HK2 expression, leading to impairment of glucose metabolism (4) . Although overexpression of TRAF4 has been reported in several types of carcinoma (5) , its biological function in tumorigenesis remains to be elucidated.
Girders of actin filament (Girdin) is activated by Akt-induced phosphorylation in response to epidermal growth factor receptor (EGFR) signaling and insulin-like growth factor 1 stimulation (6,7); the Girdin-Gai molecular complex binds to EGFR to determine whether cells migrate or proliferate (8) . Girdin has been observed to facilitate cell migration and metastasis in breast and colon cancer (9) (10) (11) , and its expression has been correlated with histological grade and distant metastasis in breast cancer (12) .
TRAF4 regulates a set of cancer-related genes that are involved in biological processes such as migration, invasion, metastasis and angiogenesis, in which Girdin is strongly implicated (13) . Therefore, it is considered as the member of the TRAF family that may influence Girdin. TRAF4 and Girdin have been implicated in the phosphatidylinositol 3-kinase (PI3-K)/Akt signal transduction pathway, which is central to cancer progression (14) . TRAF4 was reported to activate Akt, a pivotal cell survival kinase, through ubiquitination in lung cancer. In addition, TRAF4 was identified to mediate activation of nuclear factor-κB (NF-κB) through glucocorticoid-induced tumor necrosis factor receptor (15) . The p65 and p50 forms of NF-κB interact physically with signal transducer and activator of transcription-3 (STAT3), facilitating NF-κB recruitment to STAT3 promoters (16) . Girdin was previously demonstrated to be a direct target of STAT3 (17) , suggesting that TRAF4 may influence Girdin through NF-κB-mediated STAT3 activity.
Based on these observations, the present study hypothesized that TRAF4 and Girdin cooperate in tumor invasion Expression of tumor necrosis factor receptor-assicated factor 4 correlates with expression of Girdin and promotes nuclear translocation of Girdin in breast cancer and metastasis. To test this hypothesis, the expression status of Girdin in breast cancer cells and its association with TRAF4 was investigated. The results may aid in the development of novel methods for the management of breast cancer treatment. The following primary antibodies were used: Anti-Girdin (human), anti-TRAF4 (rabbit), anti-β-actin (mouse) and anti-lamin B1 (goat; Santa Cruz Biotechnology, Texas, TX, USA). Anti-mouse and anti-rabbit IgG secondary antibodies conjugated with horseradish peroxidase were purchased from Santa Cruz Biotechnology. Biotinylated secondary antibodies (anti-mouse/rabbit, Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China) were used for immunohistochemistry and fluorescein isothiocyanate (FITC)/tetramethylrhodamine (TRITC)-conjugated secondary antibodies (anti-rabbit and anti-mouse, respectively; Santa Cruz Biotechnology) were used for immunofluorescence.
Materials and methods

Patients
Cell lines and cell culture. The non-tumorigenic mammary epithelial cell line MCF-10A, and the breast cancer cell lines MCF-7 and MDA-MB-231 were obtained from the American Type Culture Collection (Manassas, VA, USA).
MCF-7 cells and MCF-10A cells were grown in H-DMEM medium and MDA-MB-231 cells were grown in Leibovitz's L-15 medium. All culture media contained 10% FBS supplemented with 100 IU/ml penicillin and 100 µg/ml streptomycin (Invitrogen Life Technologies, New York, NY, USA). The cells were cultured at 37˚C in a humidified atmosphere with 5% CO 2 .
Plasmids and transfection. The pcDNA3-TRAF4 plasmid (plasmid 16375) was purchased from Addgene (Cambridge, MA, USA). MCF-7 cells were transiently transfected using Attractene Transfection Reagent or HiPerFect Transfection Reagent (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Untransfected MCF-7 cells and cells transfected with empty plasmid were used as negative controls. Lamin B1 was used as a nuclear internal control and β-actin was used as a cytoplasmic internal control.
Preparation of nuclear and cytoplasmic extracts.
To detect the cellular localization of Girdin, nuclear and cytoplasmic fractions were isolated using the Pierce NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific; Rockford, IL, USA) according to the manufacturer's instructions.
Immunohistochemistry. The anti-Girdin and anti-TRAF4 primary antibodies (1:100) were incubated at 4˚C overnight, followed by incubation with biotinylated secondary antibodies at 37˚C for 20 min. The peroxidase reaction was developed with DAB (Fuzhou Maixin Biotechnology Development Co., Ltd.). Hematoxylin was used as a counterstain, and the sections were dehydrated in alcohol prior to being mounted on slides. The primary antibodies were replaced with phosphate-buffered saline (PBS) for the negative control.
Western blot analysis. Proteins were extracted using radioimmunoprecipitation assay (RIPA) buffer containing a protease and phosphatase inhibitor cocktail (Beyotime, Shanghai, China). The protein concentrations were determined using a Bicinchoninic Acid Protein Assay kit (Beyotime Institute of Biotechnology). Equal amounts of protein from the samples were separated by 8% SDS-PAGE and transferred to polyvinylidene fluoride membranes (EMD Millipore; Bedford, MA, USA). The membranes were blocked with 5% non-fat milk in PBS, prior to incubation with the primary antibodies against Girdin (1:200), TRAF4 (1:200), β-actin (1:1,000) or lamin B1 (1:500). The membranes were then incubated with the respective secondary antibody (1:2,000) and the protein bands were imaged using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). The protein expression was quantified using ImageJ (National Institute of Health, Bethesda, MD, USA).
Immunofluorescence. The cells were seeded in Nunc 24-well plates (Thermo Fisher Scientific) at a density of 2x10 4 cells/well, fixed with 4% paraformaldehyde (Invitrogen Life Technologies) and permeabilized with 0.2% Triton X-100. Subsequent to blocking with 5% BSA in PBS, the cells were incubated with either Girdin (1:50) or TRAF4 (1:50) primary antibody at 4˚C overnight, followed by incubation with a FITC/TRITC-conjugated secondary antibody (1:50; Santa Cruz Biotechnology) for 2 h at room temperature. The nuclei were stained with DAPI (Beyotime Institute of Biotechnology) and the cells were examined under a Leica DM5500 B microscope (Leica Microsystems GmbH, Wetzlar, Germany).
Statistical analysis. All statistical analyses were performed using SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA). Pearson's χ 2 test was used to determine correlations between TRAF4/Girdin coexpression and clinicopathological factors. Spearman's correlation test was used to determine the association between TRAF4 and Girdin expression (positive vs. negative). Independent-samples t-test was used to compare data between two groups. One-way analysis of variance and Bonferroni correction were used to compare data between three or more groups. The data are expressed as the means ± standard deviation. P<0.05 was considered to indicate a statistically significant difference. Fig. 1 ; Table I ). However, more intense staining patterns were observed in invasive ductal carcinoma (IDC) tissue samples compared with ductal carcinoma in situ (DCIS) tissue samples, and TRAF4/Girdin coexpression was significantly correlated with lymph node metastasis in tissue samples from patients.
Results
Overexpression of TRAF4 correlates with Girdin expres-
Further analyses indicated that the coexpression of TRAF4 and Girdin proteins was significantly higher in c-erbB2-negative cases as compared with c-erbB2-positive cases (66.67 vs. 17.39%). By contrast, no significant differences in coexpression rates were observed between samples that were positive or negative for the estrogen receptor, progesterone receptor or p53 (Table I) .
The association between the positive and negative cytoplasmic expression rates of TRAF4 and Girdin in breast cancer cells are summarized in Table II . There were a total of 35 samples displaying positive cytoplasmic expression of TRAF4 protein. Of these, 14 samples were Girdin-negative while 21 were Girdin-positive. By contrast, 3 samples were TRAF4-negative, all of which were Girdin-negative. These observations demonstrated that the expression of Girdin in the cytoplasm of breast cancer tissues was positively correlated with expression of TRAF4 (P<0.05).
Expression patterns of Girdin protein in breast cancer cell lines.
The levels of Girdin protein were compared in three breast cell lines: MCF-10A, normal human breast epithelia; MCF-7, ER-positive weakly invasive luminal A breast cancer cells (18) ; and MDA-MB-231, ER-negative highly proliferative and invasive triple-negative breast cancer cells (18) . Western blot analysis and relative quantification indicated that the Girdin protein was highly expressed in MDA-MB-231 and MCF-7 breast cancer cell lines; whereas only trace amounts were observed in normal MCF-10A breast cells (Fig. 2A) .
The cell extracts were separated into cytoplasmic and nuclear fractions, and the relative abundance of Girdin in the fractions were analyzed by Western blotting (Fig. 2B) . In agreement with a previous observation (7), Girdin was more strongly expressed in c-erbB2-positive tumor tissues than c-erbB2-negative tissues, and the western blotting results demonstrated that Girdin was more highly expressed in the cytoplasm of the weakly invasive MCF-7 cells than in the strongly invasive MDA-MB-231 cells.
The expression and localization of Girdin protein in MCF-7 and MDA-MB-231 breast cancer cells was evaluated Table I . Correlations between TRAF4 and Girdin coexpression and clinicopathological features. (Fig. 2C) . The fluorescent staining patterns indicated that Girdin was mainly localized in the cytoplasm in MCF-7 and MDA-MB-231 cells; however it was also detectable in the nuclei of the MDA-MB-231 cells. These observations are consistent with the immunohistochemical and immunofluorescence results ( Fig. 1 and Fig. 3, respectively) , which indicated that Girdin was mainly localized in the cytoplasm in breast cancer tissues, with no significant staining in the nuclei.
TRAF4/Girdin coexpression ---------------------------------------
Girdin expression ---------------------------------------------
TRAF4 and Girdin colocalize in the cytoplasm of breast cancer cells. Immunohistochemistry indicated that cytoplasmic overexpression of TRAF4 and Girdin were positively correlated in breast cancer cells. In order to verify these results, immunofluorescence experiments were performed. These demonstrated that TRAF4 and Girdin proteins colocalized in the cytoplasm of MCF-7 and MDA-MB-231 breast cancer cells (Fig. 3) .
TRAF4 promotes the translocation of Girdin from the cytoplasm to the nuclei in breast cancer cells.
Previous studies had demonstrated that TRAF4 was essential for the migration of normal mammary epithelial and breast cancer cells (2, 3) ; Girdin has also been implicated in migration and metastasis (9) (10) (11) . In order to determine whether the molecular mechanisms of TRAF4-induced migration involved the regulation of Girdin expression, TRAF4 was overexpressed in the weakly invasive MCF-7 breast cancer cell line. However, no significant increase in the overall Girdin protein levels were observed compared with untransfected cells or empty vector controls (P>0.05; Fig. 4A ). Therefore, Girdin protein levels in the cytoplasm and nuclei of transfected MCF-7 cells were analyzed individually by western blotting. The results revealed that overexpression of TRAF4 significantly reduced cytoplasmic expression of Girdin (P<0.05) but significantly increased its nuclear expression (P<0.05; Fig. 4B and C).
Discussion
Girdin is an actin-binding protein that is essential in remodeling the actin cytoskeleton (19) . It is also important for cell motility and is implicated in tumor progression (13) . TRAF4 is required for Akt Ub-Lys63 ubiquitination (4), which is essential for Akt activity (20, 21) . TRAF4 is also associated with NF-κB activation, and thereby STAT3 transcription. As Girdin is activated by Akt and has been identified as a direct target of STAT3 (16), TRAF4 may potentially influence Girdin via the Akt signaling pathway. However, the association between TRAF4 and Girdin and the underlying mechanisms of action remain to be established.
The current study demonstrated that the cytoplasmic overexpression of TRAF4 in breast cancer tissues was positively correlated with cytoplasmic expression of Girdin. In addition, it was observed that TRAF4 was more highly expressed in the cytoplasm of breast cancer cells than in normal breast cells; that TRAF4 and Girdin were more highly expressed in IDC tissue samples than in DCIS tissue samples; and that coexpression of TRAF4 and Girdin was higher in tissue samples taken from patients with lymph node metastases than those without metastasis.
A previous study reported that Girdin expression was significantly correlated with c-erbB2 and Ki67 expression, by demonstrating that Girdin expression was significantly higher in c-erbB2-and Ki67-positive cases than in c-erbB2-and Ki67-negative cases (12) . In the current study, it was observed that TRAF4 and Girdin coexpression was significantly higher in tissues from c-erbB2-negative cases than in tissues from c-erbB2-positive cases. However, further analysis is required to verify this finding.
Although Girdin expression has previously been identified in MDA-MB-231 breast cancer cells (9, 17) , the expression levels were not compared with normal breast cell lines or other breast cancer cell lines. In the current study, Girdin expression levels were analyzed in normal MCF-10A breast cells and ER-positive MCF-7 breast cancer cells, in addition to ER-negative MDA-MB-231 cells. It was demonstrated that the expression levels of Girdin were lower in normal breast cells compared to breast cancer cells (P<0.01), and were higher in ER-positive MCF-7 cells than in ER-negative MDA-MB-231 cells. However the difference between the two breast cancer cell lines was not statistically significant.
Consistent with a previous study that examined immunohistochemical staining patterns of Girdin in breast cancer tissues (7), the immunofluorescence observations of the present study revealed that Girdin was mainly localized in the cytoplasm of breast cancer cells. To further explore the association between TRAF4 and Girdin in breast cancer, TRAF4 was overexpressed in MCF-7 cells to determine the effect on cytoplasmic and nuclear expression of Girdin. These results demonstrated that the overexpression of TRAF4 promoted translocation of Girdin from the cytoplasm to the nuclei in breast cancer cells. This finding remains to be verified in the highly invasive MDA-MB-231 cell line.
In conclusion, the present study demonstrated that cytoplasmic expression of TRAF4 was positively correlated with cytoplasmic expression of Girdin in breast cancer cells, and that the coexpression of TRAF4 and Girdin was highest in patients with lymph node metastases. Furthermore, it was observed that Girdin was predominantly expressed in the cytoplasm of breast cancer cells, but that TRAF4 was able to promote its translocation from the cytoplasm to the nucleus. Although the underlying mechanisms remain to be established, the present findings suggest that cytoplasmic expression of TRAF4 is a potential novel marker for migration in breast cancer.
